Myeloid-derived suppressor cells in cancer: Recent progress and prospects

Immunology and Cell Biology

Volumn 91, Issue 8, 2013, Pages 493-502

  Khaled, Yazan S ^a,b,c,d,e   Ammori, Basil J ^a,b,c,d   Elkord, Eyad ^a,b,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SALFORD   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Cancer; Clinical significance; Expansion; Myeloid derived suppressor cells; Therapeutic target

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; RETINOIC ACID;

BONE MARROW CELL; BREAST CANCER; COLON CANCER; COLORECTAL CANCER; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; MYELOID DERIVED SUPPRESSOR CELL; NEOPLASM; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SARCOMA; STOMACH CANCER; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOGENESIS; HUMANS; IMMUNE TOLERANCE; IMMUNITY; IMMUNOTHERAPY; MYELOID CELLS; NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84884252997     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.29     Document Type: Review

References (112)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13: 828-835.
3. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-9307.
4. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immuno 2012; 12: 253-268.
5. Gabrilovich DI, Bronte V, Chen S-H, Colombo MP, Ochoa A, Ostrand-Rosenberg S et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67: 425-425.
6. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-5802.
7. Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995; 92: 6254-6258.
8. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002; 51: 293-298.
9. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-999.
10. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-4244.
11. Hestdal K, Ruscetti F, Ihle J, Jacobsen S, Dubois C, Kopp W et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol 1991; 147: 22-28.
12. Qu P, Boelte KC, Lin PC. Negative regulation of myeloid-derived suppressor cells in cancer. Immunol Invest 2012; 41: 562-580.
13. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 2012; 91: 167-181.
14. Dietlin TA, Hofman FM, Lund BT, Gilmore W, Stohlman SA, van der Veen RC. Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. J Leukoc Biol 2007; 81: 1205-1212.
15. Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PloS One 2012; 7: e31524.
16. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13: 721s-726s.
17. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689.
18. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001; 61: 4756-4760.
19. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58: 49-59.
20. Lechner M, Megiel C, Russell S, Bingham B, Arger N, Woo T et al. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 2011; 9: 90.
21. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16: 348-353.
22. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69: 1553-1560.
23. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012; 18: 5212-5223.
24. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
25. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65: 9525-9535.
26. Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G et al. Tumorexpressed inducible nitric oxide synthase controls induction of functional myeloidderived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 2012; 188: 5365-5376.
27. Qu P, Yan C, Blum JS, Kapur R, Du H. Myeloid-specific expression of human lysosomal acid lipase corrects malformation and malfunction of myeloid-derived suppressor cells in lal-/- mice. J Immunol 2011; 187: 3854-3866.
28. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008; 181: 4666-4675.
29. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-2043.
30. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011; 71: 2664-2674.
31. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acadl Sci USA 2006; 103: 12481-12486.
32. Zhao JL, Rao DS, Boldin MP, Taganov KD, O'Connell RM, Baltimore D. NF-kB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 2011; 108: 9184-9189.
33. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005; 175: 4583-4592.
34. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170: 270-278.
35. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD et al. Transforming growth factor-b production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-1752.
36. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage- mediated T cell deletion. J Immunol 2005; 174: 4880-4891.
37. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005; 65: 11743-11751.
38. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32: 19-25.
39. Bogdan C. Regulation of lymphocytes by nitric oxide. Methods Mol Biol 2011; 677: 375-393.
40. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044-3048.
41. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al. Abrogation of TGFb signaling in mammary carcinomas recruits Gr-1+ CD11b+ myeloid cells that promote metastasis. Cancer cell 2008; 13: 23-35.
42. Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB. Nitric oxideindependent CTL suppression during tumor progression: association with arginaseproducing (M2) myeloid cells. J Immunol 2003; 170: 5064-5074.
43. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J et al. Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123-1131.
44. Yang R, Cai Z, Zhang Y, Yutzy WH, Roby KF. Roden RBS. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+ CD11b+ myeloid Cells. Cancer Res 2006; 66: 6807-6815.
45. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloidderived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70: 68-77.
46. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5: 641-654.
47. Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222: 180-191.
48. Rodriguez P, Zea A, Ochoa A. Mechanisms of tumor evasion from the immune response. Cancer Chemother Biol Response Modif 2003; 21: 351-364.
49. Gehad AE, Lichtman MK, Schmults CD, Teague JE, Calarese AW, Jiang Y et al. Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. J Invest Dermatol 2012; 132: 2642-2651.
50. Szuster-Ciesielska A, Hryciuk-Umer E, Stepulak A, Kupisz K, Kandefer-Szerszen M. Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. Acta Oncol 2004; 43: 252-258.
51. Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 2003; 81: 664-673.
52. Agostinelli E, Seiler N. Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino acids 2006; 31: 341-355.
53. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182: 5693-5701.
54. He J, Xu Q, Jing Y, Agani F, Qian X, Carpenter R et al. Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation. EMBO R 2012; 13: 1116-1122.
55. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005; 202: 931-939.
56. Kamiyama M, Pozzi A, Yang L, DeBusk L, Breyer R, Lin P. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 2006; 25: 7019-7028.
57. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P. PGE2-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest 2012; 41: 635-657.
58. Veltman JD, Lambers MEH, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JGJV et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC cancer 2010; 10: 464.
59. Letterio JJ, Roberts AB. Regulations of immune responses by TGF-b. Annu Rev Immunol 1998; 16: 137-161.
60. Chikamatsu K, Sakakura K, Toyoda M, Takahashi K, Yamamoto T, Masuyama K. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck. Cancer Sci 2012; 103: 976-983.
61. Fu H, Hu Z, Wen J, Wang K, Liu Y. TGF-b promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin 2009; 41: 648-656.
62. Lu Y, Jiang F, Zheng X, Katakowski M, Buller B, To SST et al. TGF-b1 promotes motility and invasiveness of glioma cells through activation of ADAM17. Oncol Rep 2011; 25: 1329-1335.
63. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V et al. Tumorinfiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012; 189: 5602-5611.
64. Tan MCB, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182: 1746-1755.
65. Centuori SM, Trad M, LaCasse CJ, Alizadeh D, Larmonier CB, Hanke NT et al. Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-b-induced differentiation of CD4+ CD25+ FoxP3+ Tregs from CD4+ CD25- FoxP3- T cells. J Leukoc Biol 2012; 92: 987-997.
66. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68: 5439-5449.
67. Chatterjee SDS, Chakraborty P, Manna A, Chatterjee M, Choudhuri SK. Myeloid derived suppressor cells (MDSCs) can induce the generation of Th17 response from naive CD4(+) T cells. Immunobiology 2012; 218: 718-724.
68. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70: 99-108.
69. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P et al. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207: 2439-2453.
70. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67: 9518-9527.
71. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102: 2138-2145.
72. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72: 876-886.
73. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 2011; 9: e1001162.
74. Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J et al. TNF signaling drives myeloidderived suppressor cell accumulation. J Clin Invest 2012; 122: 4094-4104.
75. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000; 165: 779-785.
76. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang L, Cohen PA et al. Tumor-induced CD11b+ Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 2008; 181: 3291-3300.
77. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001; 166: 5398-5406.
78. Qu P, Yan C, Du H. Matrix metalloproteinase 12 overexpression in myeloid lineage cells plays a key role in modulating myelopoiesis, immune suppression, and lung tumorigenesis. Blood 2011; 117: 4476-4489.
79. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y et al. Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer cell 2004; 6: 409-421.
80. Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J et al. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother 2012; 35: 502-512.
81. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60: 1419-1430.
82. Duffy A, Zhao F, Haile L, Gamrekelashvili J, Fioravanti S, Ma C et al. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol Immunother 2012; 62: 299-307.
83. Sun HL, Zhou X, Xue YF, Wang K, Shen YF, Mao JJ et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol 2012; 18: 3303-3309.
84. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PloS One 2013; 8: e57114.
85. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 2010; 11: 1039-1046.
86. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 2012; 381: 14-22.
87. Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M et al. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother 2010; 33: 817-827.
88. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R et al. All-transretinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003; 63: 4441-4449.
89. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 2007; 67: 11021-11028.
90. Iclozan C, Antonia S, Chiappori A, Chen D-T, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013; 62: 909-918.
91. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kü bler H et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008; 14: 8270-8278.
92. Eisenstein S, Coakley BA, Briley-Saebo K, Ma G, Meseck M, Ward S et al. Myeloid derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res (e-pub ahead of print 27 March 2013; doi: 10.1158/0008-5472).
93. Kusmartsev S, Eruslanov E, Kü bler H, Tseng T, Sakai Y, Su Z et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. The J Immunol 2008; 181: 346-353.
94. Roth F, Adriana C, Vella JL, Zoso A, Inverardi L, Serafini P. Aptamer-mediated blockade of IL4Ra triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 2012; 72: 1373-1383.
95. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloidderived suppressor cell function. J Exp Med 2006; 203: 2691-2702.
96. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 2005; 102: 4185-4190.
97. Zheng Y, Xu M, Li X, Jia J, Fan K, Lai G. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol 2013; 54: 74-83.
98. Wilcox RA, Nevala WK, Thompson MA, Witzig TE, Ansell SM, Markovic SN et al. CD14+HLA-DR-/lo myeloid-derived suppressor cells express immunosuppressive B7-H family members and are depleted following taxane-based chemotherapy in melanoma. American Society Hematology Annual Meeting Abstracts; New Orleans. Blood 2009; 114: 464.
99. Gabitass RF, Crawshaw J, Pandha HS, Middleton GW. Use of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy to reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and esophagogastric cancer (EGC) American Society Clinical Oncology Annual Meeting, Chicago. J Clin Oncol 2011; 29: 296.
100. Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2012; 19: 57-64.
101. Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand- Rosenberg S. Lung cancer patients' CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008; 57: 1493-1504.
102. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S et al. IL4Ra+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009; 182: 6562-6568.
103. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH et al. Population alterations of l-arginase-and inducible nitric oxide synthase-expressed CD11b+/CD14-/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136: 35-45.
104. Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X et al. Immunosuppressive CD14+ HLA-DRlow/- monocytes in prostate cancer. Prostate 2009; 70: 443-455.
105. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T Cells. Gastroenterology 2008; 135: 234-243.
106. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-4513.
107. Pan PY, Wang GX, Yin B, Ozao J, Ku T, Divino CM et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111: 219-228.
108. Menetrier-Caux C, Montmain G, Dieu M, Bain C, Favrot M, Caux C et al. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92: 4778-4791.
109. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007; 67: 10019-10026.
110. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocytemacrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-6343.
111. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150-4166.
112. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116: 2777-2790.